OUR STORY & MISSION
Founded in 2024 out of a desire to save the most vulnerable from the world's threat of treatment resistant infections, our mission is to develop innovative therapies that combat antibiotic resistance and viral threats and associated cancers, ensuring effective treatments are accessible to patients worldwide and helping to save the lives of future generations.

MEET THE TEAM
At Blue Sky Pharmaceuticals, our team is comprised of highly skilled professionals with extensive expertise in drug discovery and development.
Further, our board includes experts with significant backgrounds in clinical development and regulatory affairs, ensuring that our innovative therapies are developed with the highest standards of scientific excellence and compliance.
Together, our team's diverse backgrounds and contributions to science position Blue Sky Pharmaceuticals at the forefront of addressing critical global health challenges.
TIMELINE
We're just getting started. Watch our early traction and success as we grow.
OUR EUROPEAN HQ
We’re based in Dublin, Ireland
Having our headquarters in Dublin allows us to benefit from the strong and growing pharmaceutical industry that exists in Ireland. This gives us access to a highly skilled workforce and innovative research institutions, while placing us at the heart of a growing biotech hub.


OUR UNITED STATES LOCATION
Our US Office is in Dover, Delaware
Having our headquarters in Dover, Delaware, provides significant advantages due to our proximity to groundbreaking research facilities and key government agencies like BARDA and the NIH, as well as major drug discovery hubs such as Cambridge, MA, and the Maryland/DC Metro area. This location fosters collaboration with leading institutions, accelerates our drug development efforts, and enhances our ability to navigate regulatory pathways and access funding opportunities, all while connecting us to a highly skilled workforce in a vibrant biotech ecosystem.
Want to Chat About
Our Pipeline?
Fill out the form below to get started.



